The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate
- Title
- The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate
- Author
- 김승현
- Keywords
- Amyotrophic lateral sclerosis; Prognostic factors; Neurotrophic factors; Mesenchymal stromal cells
- Issue Date
- 2012-01
- Publisher
- Elsevier Science B.V., Amsterdam
- Citation
- Special Issue: Stress and neurological disease, Experimental Neurology, January 2012, 233(1), p.72-480
- Abstract
- Amyotrophic lateral sclerosis (ALS) is caused by motor neuron death. The relationship between the prognosis of ALS patients and the function of their bone marrow mesenchymal stromal cells (BM-MSCs) is unclear. We designed this study to assess the correlation between the progression rate of the ALS Functional Rating Scale-revised version (ΔFS), which is reported to predict prognosis, and the pluripotency and trophic factor secreting capacity of ALS patients' BM-MSCs. We evaluated ΔFS in 23 ALS patients and isolated BM-MSCs from those patients and five healthy people. Levels of Nanog, Oct-4, and Nestin mRNA were examined to evaluate pluripotency, and levels of BDNF, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1β, SDF-1α, GDNF, VEGF, and ANG mRNA were examined to assess trophic factor secreting capacity. In addition, we measured the protein levels of Nanog, Oct-4, Nestin, SDF-1α, ANG, bFGF-2, VEGF, IGF-1, GDNF, and BDNF. mRNA levels of Nanog, Oct-4, ECGF1, bFGF-2, HGF, IGF-1, PGF, TGF-1β, SDF-1α, GDNF, VEGF, and ANG were negatively correlations with ΔFS. However, those of Nestin and BDNF were not significantly correlated with ΔFS. Similarly, Nanog, Oct-4, SDF-1α, ANG, bFGF-2, VEGF, IGF-1, and GDNF protein levels had a significant negative correlation with ΔFS. Results indicate that the pluripotency and trophic factor secreting capacity of the BM-MSCs of ALS patients are reduced in proportion to a poorer prognosis. We therefore suggest that healthy allogeneic BM-MSCs might be a better option for cell therapy in ALS patients.
- URI
- https://www.sciencedirect.com/science/article/pii/S0014488611004250https://repository.hanyang.ac.kr/handle/20.500.11754/69356
- ISSN
- 0014-4886
- DOI
- 10.1016/j.expneurol.2011.11.021
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML